Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single- and Multiple-Dose IV LY3002813 in Mild Cognitive Impairment and Alzheimer's Disease
jRCT2080223143Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing LY3002813 IV with Placebo IV (2 arms). Primary endpoints: Safety and tolerability of LY3002813, Pharmacokinetics of LY3002813 and 1 more. Started Mar 2016; status: recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080223143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223143.